Protara Therapeutics Stock Price

-0.27 (-3.22%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Protara Therapeutics Inc TARA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.27 -3.22% 8.11 13:25:37
Open Price Low Price High Price Close Price Prev Close
8.33 8.07 8.48 8.38
Bid Price Ask Price Spread News
8.08 8.14 0.06 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
212 13,083 $ 8.19 $ 107,206 - 8.00 - 36.69
Last Trade Time Type Quantity Stock Price Currency
13:25:49 10 $ 8.14 USD


Draw Mode:

Protara Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 91.06M 11.23M 7.60M $ - $ - -4.73 -2.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 229.89k 11.40%

more financials information »

Protara Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TARA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.178.998.008.5041,134-0.06-0.73%
1 Month10.3310.548.008.9570,356-2.22-21.49%
3 Months11.0811.35728.009.73112,658-2.97-26.81%
6 Months19.5022.988.0013.19118,627-11.39-58.41%
1 Year25.5936.698.0016.44100,834-17.48-68.31%
3 Years25.2067.0798.0017.9171,656-17.09-67.82%
5 Years25.2067.0798.0017.9171,656-17.09-67.82%

Protara Therapeutics Description

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).

Your Recent History
Protara Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.